化合物 Ketorolac hemicalcium,Ketorolac hemicalcium

化合物 Ketorolac hemicalcium|T60496|TargetMol

價格	￥6230
包裝	1g

最小起訂量	1g
發(fā)貨地	上海
更新日期	2024-12-12

QQ交談微信洽談

產品詳情

中文名稱:化合物 Ketorolac hemicalcium	英文名稱:Ketorolac hemicalcium
CAS:167105-81-9	品牌: TargetMol
產地: 美國	保存條件: Shipping with blue ice.
產品類別: 抑制劑
貨號: T60496

Product Introduction

Bioactivity

Name	Ketorolac hemicalcium
Description	Ketorolac (RS37619) hemicalcium is a nonselective COX inhibitor with IC50s of 20 nM and 120 nM for COX-1 and COX-2, respectively. Ketorolac hemicalcium is a non-steroidal anti-inflammatory drug (NSAID) that is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac hemicalcium is also a DDX3 inhibitor that can be used in cancer research [1] [4].
In vitro	Ketorolac (RS37619) salt (0-30 μM, 48 h) effectively kills the oral cancer cells [4]. Ketorolac salt (0-5 μM, 48 h) inhibits the expression of DDX3 protein, and induces apoptosis in H357 cells [4]. Ketorolac salt (0-2.5 μM, 0-16 h) inhibits the proliferation of oral cancer cells [4]. Ketorolac salt (0-50 μM) directly interacts with DDX3 and inhibits the ATPase activity [4]. Cell Viability Assay [4] Cell Line: HOK, SCC4, SCC9 and H357 cells Concentration: 0-30 μM Incubation Time: 48 h Result: Showed inhibition with IC 50 s of 2.6, 7.1 and 8.1 μM against H357, SCC4 and SCC9 cells, respectively. And the normal HOK cell line did not show any cell death effect. Cell Proliferation Assay [4] Cell Line: H357 Concentration: 0.5, 1.0, 1.5, 2.0 and 2.5 μM Incubation Time: 0, 8 and 16 h Result: Inhibited the proliferation. Western Blot Analysis [4] Cell Line: H357 Concentration: 1, 2.5 and 5 μM Incubation Time: 48 h Result: Significantly reduced DDX3 protein expression levels, but not completely ablated as compared to DMSO treated cells. Up regulated the expression of E-cadherin. Apoptosis Analysis [4] Cell Line: H357 Concentration: 2.5 and 5 μM Incubation Time: 48 h Result: Induced apoptosis.
In vivo	Ketorolac (RS37619) (0.4% ketorolac tromethamine ophthalmic solution) shows powerful ocular anti-inflammatory activities in rabbits [1]. Ketorolac (4 mg/kg/day, p.o.; 2 weeks) has no detrimental effect in the volume fraction of bone trabeculae formed inside the alveolar socket in rats [2]. Ketorolac (60 μg; intrathecal injection; once) attenuates the damage caused by spinal cord ischemia in rats [3]. Ketorolac salt (20 and 30 mg/kg; i.p.; two times in a week for 3 weeks) reduces oral carcinogenesis in mice [4]. Animal Model: New Zealand White rabbits (2.0–2.7 kg), LPS endotoxin-induced ocular inflammation [1] Dosage: 50 μL ketorolac tromethamine ophthalmic solution 0.4% Administration: In eyes, twice, 2 hours and 1 hour before LPS challenge Result: Resulted in a nearly complete inhibition (98.7%) of LPS endotoxin-induced increases in FITC (fluorescein isothiocyanate)-dextran in the anterior chamber, and resulted in a nearly complete inhibition (97.5%) of LPS endotoxin-induced increases in aqueous PGE 2 concentrations in the aqueous humor. Animal Model: Male Wistar rats (400–450 g), spinal cord ischemia model [3] Dosage: 30 and 60 μg Administration: Intrathecal injection, 1 h before the ischemia induction for once Result: Significantly reduced the motor disturbances and improved the survival rate at 60 μg. Animal Model: BALB/c mice, oral carcinogenesis model [4] Dosage: 20 mg/kg and 30 mg/kg Administration: IP injection, two times in a week for 3 weeks Result: Decreased tumor burden, reduced expression of DDX3 and anti-apoptotic proteins (Bcl-2 and Mcl-1).
Storage	Shipping with blue ice.

關鍵字： Ketorolac hemicalcium|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領域科學家的研究提供專業(yè)的產品和服務。TargetMol?品牌的客戶群分布于40多個國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產品，包括12000多種抑制劑、16000多種天然產物和各類多肽、抗體、生命科學試劑盒等，此外，我們還建設有CADD（計算機輔助藥物設計）研究中心、藥理實驗室、藥化合成平臺三大技術中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質的產品和服務、快速高效的全球供應鏈和專業(yè)的技術支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結果。

成立日期	2013-04-18 （12年）	注冊資本	566.265100萬人民幣
員工人數	100-500人	年營業(yè)額	￥ 1億以上
主營行業(yè)	天然產物,生化試劑,分子生物學,分子砌塊,生物技術服務	經營模式	貿易,工廠,試劑,定制,服務

TargetMol中國（陶術生物）

VIP 3年

公司成立：12年
注冊資本：566.265100萬人民幣
企業(yè)類型：有限責任公司(自然人投資或控股)
主營產品：小分子抑制劑、藥物篩選化合物庫、藥物篩選等
公司地址：靜安區(qū)江場三路238號8樓

進入店鋪

詢盤

店內推薦

p38α抑制劑3|T67830|TargetMol

￥111

FR179642 (hydrate)|T36024|TargetMol

￥560

阿維A鈉|T22548|TargetMol

￥16800

化合物 Ketorolac hemicalcium|T60496|TargetMol相關廠家報價

產品名稱	價格		公司名稱	報價日期
Vidofludimus hemicalcium/4sc-101 hemicalcium;/SC12267 hemicalcium)	詢價	VIP1年	寶雞締都醫(yī)藥化工有限公司	2024-11-25
化合物 T10895	詢價	VIP1年	青島愷潤生物醫(yī)藥科技有限公司	2025-01-19
化合物 T10110	詢價	VIP3年	陜西締都新材料有限公司	2024-12-18

內容聲明:
以上所展示的信息由商家自行提供，內容的真實性、準確性和合法性由發(fā)布商家負責。商家發(fā)布價格指該商品的參考價格，并非原價，該價格可能隨著市場變化，或是由于您購買數量不同或所選規(guī)格不同而發(fā)生變化。最終成交價格，請咨詢商家，以實際成交價格為準。請意識到互聯(lián)網交易中的風險是客觀存在的